Some Investors May Be Worried About Sycal Ventures Berhad's (KLSE:SYCAL) Returns On Capital
If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business. Analysts use this formula to calculate it for Sycal Ventures Berhad:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
0.026 = RM8.2m ÷ (RM484m - RM169m) (Based on the trailing twelve months to September 2024).
Therefore, Sycal Ventures Berhad has an ROCE of 2.6%. Ultimately, that's a low return and it under-performs the Construction industry average of 11%.
View our latest analysis for Sycal Ventures Berhad
While the past is not representative of the future, it can be helpful to know how a company has performed historically, which is why we have this chart above. If you want to delve into the historical earnings , check out these free graphs detailing revenue and cash flow performance of Sycal Ventures Berhad.
There is reason to be cautious about Sycal Ventures Berhad, given the returns are trending downwards. Unfortunately the returns on capital have diminished from the 4.2% that they were earning five years ago. And on the capital employed front, the business is utilizing roughly the same amount of capital as it was back then. Companies that exhibit these attributes tend to not be shrinking, but they can be mature and facing pressure on their margins from competition. If these trends continue, we wouldn't expect Sycal Ventures Berhad to turn into a multi-bagger.
All in all, the lower returns from the same amount of capital employed aren't exactly signs of a compounding machine. Investors haven't taken kindly to these developments, since the stock has declined 15% from where it was five years ago. That being the case, unless the underlying trends revert to a more positive trajectory, we'd consider looking elsewhere.
If you want to know some of the risks facing Sycal Ventures Berhad we've found 2 warning signs (1 doesn't sit too well with us!) that you should be aware of before investing here.
While Sycal Ventures Berhad may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Pfizer (PFE) Reports Promising Phase 3 Results For Bladder Cancer Treatment Combination
Pfizer recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising outcomes for PADCEV in treating muscle-invasive bladder cancer. Over the last quarter, Pfizer's stock saw an 11% rise, with these results potentially adding weight to this performance. The company also reached milestones in other research and development areas and maintained strong profitability, exemplified by a net income leap in its Q2 2025 earnings. Despite broader market trends pushing the S&P 500 and Nasdaq to record highs, Pfizer's product developments remain key contributors to its recent market position. We've spotted 2 warning signs for Pfizer you should be aware of. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource. The recent results from Pfizer's Phase 3 EV-303 trial offer promising insights for the company's oncology portfolio, potentially enhancing future revenue streams. Despite this positive development, Pfizer's shares experienced an 8.56% decline over the past year, reflecting challenges beyond short-term gains. In the broader context, Pfizer outperformed the US Pharmaceuticals industry, which saw a 16.1% decline over the same period, although it underperformed the overall US market, which returned 19.6%. The recent 11% rise in Pfizer's stock in the last quarter provides a contrast to the longer-term decline, suggesting a potential shift in investor sentiment influenced by recent successes in clinical trials. Analysts' consensus price target of approximately $28.86 suggests room for upside from the current share price of $24.65. However, projections must factor in the ongoing challenges of regulatory pressures and upcoming patent expirations, which may impact revenue and earnings forecasts. As the company continues to navigate these hurdles, the sustained advancement of its R&D initiatives remains a critical component in striving to achieve the forecasted revenue and earnings growth. Our comprehensive valuation report raises the possibility that Pfizer is priced lower than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
5 hours ago
- Yahoo
Marshalls First Half 2025 Earnings: EPS: UK£0.035 (vs UK£0.064 in 1H 2024)
Explore Marshalls's Fair Values from the Community and select yours Marshalls (LON:MSLH) First Half 2025 Results Key Financial Results Revenue: UK£319.5m (up 4.2% from 1H 2024). Net income: UK£8.90m (down 45% from 1H 2024). Profit margin: 2.8% (down from 5.2% in 1H 2024). The decrease in margin was driven by higher expenses. EPS: UK£0.035 (down from UK£0.064 in 1H 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Marshalls Earnings Insights Looking ahead, revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Basic Materials industry in the United Kingdom. Performance of the British Basic Materials industry. The company's share price is broadly unchanged from a week ago. Risk Analysis We should say that we've discovered 1 warning sign for Marshalls that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 hours ago
- Yahoo
Returns On Capital At Tri-Mode System (M) Berhad (KLSE:TRIMODE) Paint A Concerning Picture
There are a few key trends to look for if we want to identify the next multi-bagger. Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly, an expanding base of capital employed. This shows us that it's a compounding machine, able to continually reinvest its earnings back into the business and generate higher returns. Having said that, from a first glance at Tri-Mode System (M) Berhad (KLSE:TRIMODE) we aren't jumping out of our chairs at how returns are trending, but let's have a deeper look. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Understanding Return On Capital Employed (ROCE) Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. The formula for this calculation on Tri-Mode System (M) Berhad is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.028 = RM4.4m ÷ (RM173m - RM17m) (Based on the trailing twelve months to March 2025). So, Tri-Mode System (M) Berhad has an ROCE of 2.8%. Ultimately, that's a low return and it under-performs the Logistics industry average of 4.0%. Check out our latest analysis for Tri-Mode System (M) Berhad Historical performance is a great place to start when researching a stock so above you can see the gauge for Tri-Mode System (M) Berhad's ROCE against it's prior returns. If you want to delve into the historical earnings , check out these free graphs detailing revenue and cash flow performance of Tri-Mode System (M) Berhad. What The Trend Of ROCE Can Tell Us In terms of Tri-Mode System (M) Berhad's historical ROCE movements, the trend isn't fantastic. Around five years ago the returns on capital were 3.5%, but since then they've fallen to 2.8%. However, given capital employed and revenue have both increased it appears that the business is currently pursuing growth, at the consequence of short term returns. If these investments prove successful, this can bode very well for long term stock performance. Our Take On Tri-Mode System (M) Berhad's ROCE While returns have fallen for Tri-Mode System (M) Berhad in recent times, we're encouraged to see that sales are growing and that the business is reinvesting in its operations. These growth trends haven't led to growth returns though, since the stock has fallen 24% over the last five years. As a result, we'd recommend researching this stock further to uncover what other fundamentals of the business can show us. If you'd like to know more about Tri-Mode System (M) Berhad, we've spotted 5 warning signs, and 4 of them can't be ignored. While Tri-Mode System (M) Berhad may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data